MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.
Industry, Sector and Symbol
Stock Exchange ETR
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolETR:MOR
Previous Symbol
CUSIPN/A
Phone+49-89-899270
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees322
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
MorphoSys (ETR:MOR) Frequently Asked Questions
What is MorphoSys' stock symbol?
MorphoSys trades on the ETR under the ticker symbol "MOR."
What price target have analysts set for MOR?
10 analysts have issued 1 year target prices for MorphoSys' shares. Their forecasts range from €56.00 to €130.00. On average, they anticipate MorphoSys' stock price to reach €98.30 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price. View Analyst Price Targets for MorphoSys.
What is the consensus analysts' recommendation for MorphoSys?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MorphoSys.
Has MorphoSys been receiving favorable news coverage?
Media headlines about MOR stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MorphoSys earned a news impact score of 1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future.
Who are some of MorphoSys' key competitors?
Some companies that are related to MorphoSys include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are MorphoSys' key executives?
MorphoSys' management team includes the folowing people:
- Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)
- Mr. Jens H. Holstein, CFO & Member of Management Board (Age 54)
- Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 48)
- Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 56)
- Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 60)
What is MorphoSys' stock price today?
One share of MOR stock can currently be purchased for approximately €97.00.
What is MorphoSys' official website?
How can I contact MorphoSys?
MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.
MarketBeat Community Rating for MorphoSys (ETR MOR)
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
